Cargando…

Reply: “Biologics for psoriasis during COVID-19 outbreak”

Detalles Bibliográficos
Autor principal:	Di Lernia, Vito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the American Academy of Dermatology, Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146699/ https://www.ncbi.nlm.nih.gov/pubmed/32283234 http://dx.doi.org/10.1016/j.jaad.2020.04.004

Ejemplares similares

Reply to: “Biologics for psoriasis during COVID-19 outbreak”
por: Murrell, Dedee F., et al.
Publicado: (2020)

Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials
por: Di Lernia, Vito, et al.
Publicado: (2022)

Therapeutic Management of a Case of Severe Psoriasis Coexistent with Bullous Pemphigoid in the Elderly
por: Di Lernia, Vito, et al.
Publicado: (2023)

Reply to: “COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution”
por: Lebwohl, Mark, et al.
Publicado: (2020)

Biologics for Psoriasis during the COVID-19 Pandemic
por: Kamiya, Koji, et al.
Publicado: (2021)

Biologics for Psoriasis During the COVID-19 Pandemic
por: Zeng, Huanhuan, et al.
Publicado: (2021)

Reply to “The outbreak of COVID-19: An overview”
por: Wu, Yi-Chi, et al.
Publicado: (2020)

Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
por: Di Lernia, V, et al.
Publicado: (2016)

Author's Reply to Heart Transplantation to Fulminant Myocarditis during COVID-19 Outbreak
por: Kim, In-Cheol, et al.
Publicado: (2020)

COVID-19 et psoriasis chez l’enfant. Données d’une cohorte internationale
por: Zitouni, Jinane, et al.
Publicado: (2021)

Reply to letter to the editor: “Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China”
por: Cavalcante, Marcelo Borges, et al.
Publicado: (2020)

COVID, Biologics, and Psoriasis Therapy
por: Elston, Dirk M.
Publicado: (2020)

Should biologics for psoriasis be interrupted in the era of COVID-19?
por: Lebwohl, Mark, et al.
Publicado: (2020)

Dimethyl fumarate treatment for psoriasis in a real‐life setting: A multicentric retrospective study
por: Corazza, Monica, et al.
Publicado: (2021)

Fluconazole-Induced Acute Generalized Exanthematous Pustulosis
por: Di Lernia, Vito, et al.
Publicado: (2015)

Institutional versus home isolation to curb the COVID-19 outbreak – Authors' reply
por: Wilder-Smith, Annelies, et al.
Publicado: (2020)

ENT surgical emergencies during the COVID-19 outbreak
por: Pontillo, Vito, et al.
Publicado: (2021)

Safety of biologics for psoriasis patients during the COVID-19 pandemic: the experience from Wuhan, China
por: Zhao, Liang, et al.
Publicado: (2021)

In Reply to the “Letter to the Editor Regarding Telemedicine in Neurosurgery During the COVID-19 Outbreak: Where We Are 1 Year Later”
por: Mouchtouris, Nikolaos, et al.
Publicado: (2022)

Biologics and Biosimilars in Psoriasis
por: Ahmed, Sk Shahriar, et al.
Publicado: (2023)

A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting
por: Ghoreishi Amin, Nazila, et al.
Publicado: (2023)

Subacute cutaneous lupus erythematosus onset preceded by Kikuchi-Fujimoto disease
por: Di Lernia, Vito, et al.
Publicado: (2014)

Ineffectiveness of tumor necrosis factor-α blockers and ustekinumab in a case of type IV pityriasis rubra pilaris
por: Lernia, Vito Di, et al.
Publicado: (2015)

Viral Infections May Be Associated with Henoch–Schönlein Purpura
por: Nikolaishvili, Mariam, et al.
Publicado: (2023)

Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis - Reply
por: Mesquita, Priscila Miranda Diogo, et al.
Publicado: (2017)

Psoriasis Management During the COVID-19 Pandemic: Recommendations by SIG Psoriasis (IADVL Academy)
por: Ganguly, Satyaki, et al.
Publicado: (2021)

COVID-19 Outbreak: An Overview on Dentistry
por: Spagnuolo, Gianrico, et al.
Publicado: (2020)

BIOLOGICAL THERAPY OF PSORIASIS
por: Sivamani, Raja K, et al.
Publicado: (2010)

Biologics in the management of psoriasis
por: Bahner, Jennifer D, et al.
Publicado: (2009)

COVID-19 and biologics for psoriasis: A high-epidemic area experience—Bergamo, Lombardy, Italy
por: Carugno, Andrea, et al.
Publicado: (2020)

Update on biologic safety for patients with psoriasis during pregnancy
por: Porter, Martina L., et al.
Publicado: (2017)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

Reply: Biological Plausibility Behind the Benefits of Intravenous Metoprolol in Severe COVID-19
por: Santos, Arnoldo, et al.
Publicado: (2022)

Psoriasis flares after COVID-19 vaccination: adherence to biologic therapy reduces psoriasis exacerbations: a case-control study
por: Burlando, Martina, et al.
Publicado: (2023)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
por: GNESOTTO, Laura, et al.
Publicado: (2023)

Surgery during the COVID-19 pandemic – Authors' reply
por: COVIDSurg Collaborative
Publicado: (2020)

Depression and anxiety during COVID-19 – Authors' reply
por: Santomauro, Damian F, et al.
Publicado: (2022)

Reply to “The global response: how cities and provinces around the globe tackled COVID-19 outbreaks in 2021”
por: Ngo, Hoang-Anh, et al.
Publicado: (2023)

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows
por: Caiazzo, Giuseppina, et al.
Publicado: (2018)

The Psoriasis Disability Index in Romanian Psoriasis Patients during COVID-19 Pandemic: Contribution of Clinical and Psychological Variables
por: Mihu, Carina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_49r8altlpuktic2n7r6mkkh79d